While these observations may dismiss the prognosis utilities of MYLK2, as well as other recurrently perturbed actomyosin genes, e.g., MYH6 and MYH7, the specific functions of these genes still require a detailed functional interrogation in uterine as well as other cancer models. This evidence concerns the gene MYLK2 and cancer.